HAE EBITDA Growth
Haemonetics Corp · EBITDA Growth
HAE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-30.67%period ending
HAE TTM EBITDA YoY % (-76.61% → -30.67%)
Year-over-year change
High-resolution chart · PNG
HAE ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -30.6679% | |
| -22.8403% | |
| 9.847% | |
| 13.9574% | |
| 23.3999% | |
| 20.3045% | |
| 15.7047% | |
| 17.6637% | |
| 7.4233% | |
| 15.7933% | |
| 18.3688% | |
| 15.3143% | |
| 28.9355% | |
| 39.0412% | |
| 35.7349% | |
| 31.9087% | |
| 20.4672% | |
| -4.4551% | |
| -14.167% | |
| -18.1466% | |
| -25.7023% | |
| -29.0515% | |
| -17.0852% | |
| -7.9661% | |
| 9.4193% | |
| 43.3446% | |
| 46.0791% | |
| 69.7361% | |
| 62.2643% | |
| 25.7063% | |
| 26.5478% | |
| -10.0937% | |
| -13.7261% | |
| 19.0453% | |
| 0.7902% | |
| 16.8929% | |
| 22.6699% | |
| -9.3634% | |
| 14.3996% | |
| 40.0365% | |
| 92.5602% | |
| 133.0319% | |
| 42.6498% | |
| 15.5694% | |
| -28.6953% | |
| -30.9092% | |
| -9.4939% | |
| -23.0675% | |
| -0.795% | |
| -9.4215% | |
| 2.7019% | |
| 32.6901% | |
| 5.3022% | |
| -4.5535% | |
| -15.0173% | |
| -25.2359% | |
| -24.4629% | |
| -23.7267% | |
| -2.1582% | |
| -6.1749% | |
| -3.9715% | |
| 6.9928% | |
| -18.167% | |
| -11.1385% | |
| 5.5624% | |
| 22.2324% | |
| 25.0005% | |
| 44.8044% | |
| 44.3994% | |
| 29.5557% | |
| 30.96% | |
| 15.4891% | |
| -4.3583% | |
| -14.5613% | |
| -30.2501% | |
| -44.0339% | |
| -36.2178% | |
| -29.891% | |
| 20.1129% | |
| 81.3165% | |
| 61.4893% | |
| 50.8621% | |
| 13.0109% | |
| -9.6381% | |
| 1.5556% | |
| 14.773% | |
| 29.1513% | |
| 32.9972% | |
| 27.231% | |
| 15.6924% | |
| -17.329% | |
| -4.1245% | |
| -11.6064% | |
| -26.194% | |
| -16.55% | |
| -36.923% | |
| -25.9671% | |
| 10.3583% | |
| 67.7924% | |
| 94.9516% |